ACACIA-HCM: Aficamten for symptomatic nonobstructive hypertrophic cardiomyopathy

28 August 2026 (11:45 - 11:58)

Organised by:

Video

Sign in to view the resources

ESC TV

Slides

Infographic

About the speaker

Doctor Ahmad Masri

Oregon Health & Science University Medical Group, Portland (United States of America)

14 More presentations in this session

Presentation thumbnail

CARDIO-TTRansform: efficacy and safety of eplontersen in patients with transthyretin amyloid cardiomyopathy

Doctor M. Maurer (New York, US)

Presentation thumbnail

Discussant review - CARDIO-TTRansform

Professor G. Sinagra (Trieste, IT)

Presentation thumbnail

Panel discussion - CARDIO-TTRansform

Presentation thumbnail

SINGLE-AF: Anticoagulation for atrial fibrillation with intermediate stroke risk

Professor B. Joung (Seoul, KR)

Presentation thumbnail

Discussant review - SINGLE-AF

Professor I. Van Gelder (Groningen, NL)

Access the full session

Session thumbnail

HOT LINE 1

The Event

Event poster

ESC Congress 2026

28 August 2026 11:45 CET

You may be interested in

Congress Presentation

Effect of aficamten on cardiac structure and function in patients with symptomatic nonobstructive hypertrophic cardiomyopathy - Results from the ACACIA-HCM trial

29 August 2026

Congress Presentation

ODYSSEY-HCM: Mavacamten in nHCM

30 August 2025

Congress Presentation

Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM an international multicenter phase 3 trial

13 May 2024

Congress Presentation

Efficacy and safety of long-term treatment with aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy: results from FOREST-HCM

31 August 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources